Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows

v3.25.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Cash flows from operating activities:              
Net income (loss) $ 855,009 $ 967,796 $ (3,165,139) $ 946,979 $ 1,916,168 $ (5,814,558)  
Adjustments to reconcile net income (loss) to net cash provided by operating activities:              
Depreciation and amortization         1,270,776 4,166,952  
Net loss on disposition or impairment (non-cash portion)         3,752,862 5,602,641  
Net franchise fees recognized upon termination of franchise agreements         (257,797) (99,966)  
Deferred income taxes         0 67,990  
Provision for credit losses         149,719 0 $ 220,893
Stock-based compensation expense         971,138 1,475,710  
Changes in operating assets and liabilities, net of acquisitions:              
Accounts receivable         1,464,026 240,981  
Prepaid expenses and other current assets         (424,897) (53,888)  
Deferred franchise costs         382,986 456,894  
Deposits and other assets         (19,280) 15,710  
Assets and liabilities held for sale, net         0 (2,147,354)  
Accounts payable         (649,903) 276,296  
Accrued expenses         (3,475,804) 1,255,713  
Payroll liabilities         (925,440) 2,621,327  
Operating leases         (3,843,956) 0  
Deferred revenue         (1,643,696) (1,504,305)  
Upfront regional developer fees         (215,524) (346,357)  
Other liabilities         489,649 (928,850)  
Net cash (used in) provided by operating activities         (1,058,973) 5,284,936  
Cash flows from investing activities:              
Proceeds from sale of clinics         7,778,287 374,100  
Purchase of property and equipment         (1,154,385) (901,394)  
Net cash provided by (used in) investing activities         6,623,902 (527,294)  
Cash flows from financing activities:              
Payments of finance lease obligation         (4,354) (19,013)  
Purchases of treasury stock under employee stock plans         (8,440) (9,583)  
Purchases of treasury stock under employee stock plans         (2,288,994) 0  
Proceeds from exercise of stock options         1,453,558 52,098  
Repayment of debt under the Credit Agreement         0 (2,000,000)  
Net cash used in financing activities         (848,230) (1,976,498)  
Increase in cash, cash equivalents and restricted cash         4,716,699 2,781,144  
Cash, cash equivalents and restricted cash, beginning of period   $ 25,996,436   $ 19,214,292 25,996,436 19,214,292 19,214,292
Cash, cash equivalents and restricted cash, end of period 30,713,135   21,995,436   30,713,135 21,995,436 25,996,436
Reconciliation of cash, cash equivalents and restricted cash:              
Cash and cash equivalents 29,699,953   20,737,769   29,699,953 20,737,769 25,051,355
Restricted cash 1,013,182   1,257,667   1,013,182 1,257,667  
Cash, cash equivalents and restricted cash, end of period $ 30,713,135   $ 21,995,436   30,713,135 21,995,436 $ 25,996,436
Net cash paid for:              
Interest         37,917 56,668  
Income taxes         545,979 507,925  
Non-cash investing and financing activity:              
Unpaid purchases of property and equipment         $ 91,883 $ 0